Medical nanotechnology is now one of the most tangible areas of innovation for the pharmaceutical and cosmetics industries. This is not science fiction, but a set of systems already used on an industrial scale, from mRNA vaccines and oncology drugs to diagnostic devices. For professionals working in formulation development, understanding how these technologies work has become a requirement rather than an option.

In this article, we look at what lipid nanoparticles are, why they have become so important in vaccines, and which other applications are emerging in the medical and cosmetics sectors.

What Is Nanomedicine and Why Does It Matter to Pharmaceutical and Cosmetics Companies?

Nanomedicine is the application of nanotechnology in clinical settings. It operates on a dimensional scale between 1 and 100 nanometers, where materials can display different physical, chemical, and biological properties compared with the same substance at the macroscopic scale.

This change in properties is one of the main reasons nanoparticles are so relevant to companies developing pharmaceuticals and cosmetics. An active ingredient enclosed within a nanoscale structure can cross biological barriers that would otherwise be difficult to penetrate, resist degradation for longer, and reach the target tissue more precisely.

The most mature applications currently concern two main areas: diagnostics, where nanoparticles can act as contrast agents or probes for identifying diseased cells at the molecular level, and therapy, where they enable targeted drug delivery while reducing side effects. EU Regulation 2017/745 already governs the classification of medical devices containing nanomaterials according to the risks associated with their potential release into the body.

Lipid Nanoparticles: What They Are and How They Are Made

Lipid nanoparticles, or LNPs, are microscopic vesicles made from lipid components. They are capable of encapsulating a therapeutic molecule and protecting it until it is delivered.

Their popularity increased dramatically during the COVID-19 pandemic, when they became the delivery system used to transport vaccine mRNA into cells. However, LNPs did not originate with COVID-19. They are also the basis of Onpattro, the first FDA-approved siRNA-based drug, used to treat a rare form of amyloidosis.

The Main Components of a Lipid Nanoparticle

A typical LNP is not made from a single lipid, but from a combination of four components, each with a specific function:

• Ionizable lipid: at acidic pH, it becomes positively charged and binds to RNA or DNA molecules, which are negatively charged. This component makes nucleic acid encapsulation possible.
• Helper or structural lipid: contributes to the stability of the nanoparticle membrane.
• Cholesterol: strengthens the structure and promotes fusion between the nanoparticle and the cell membrane.
• PEGylated lipid: a polyethylene glycol (PEG) molecule attached to the surface, which improves solubility and extends the amount of time the nanoparticle remains in the bloodstream before being cleared.

This combination allows LNPs to perform two functions that RNA molecules could not achieve on their own: crossing the cell membrane and surviving long enough to reach the target without being degraded by enzymes in the body.

Why Lipid Nanoparticles Are Central to mRNA Vaccines

The connection between nanoparticles and vaccines stems from a very practical problem: mRNA is a fragile molecule. Without a protective carrier, it would be degraded within minutes by enzymes in the bloodstream, before it could even reach the cells.

Lipid nanoparticles solve this problem by encapsulating the mRNA and protecting it during transport. Once the target cell is reached, the LNP interacts with the cell membrane and releases its contents inside the cell, where the mRNA can be translated into protein and trigger the immune response.

Specific PEGylated lipids, such as ALC-0159, and ionizable lipids such as SM-102 have been used in COVID-19 mRNA vaccines and were specifically developed for this type of delivery. The same encapsulation principle is now being studied for other applications, from gene therapy to CRISPR genome editing, where LNPs are used to transport molecular editing tools directly into target cells, including blood stem cells.

Other Applications of Medical Nanotechnology

Beyond vaccines, medical nanotechnology covers a wide range of applications that are already in use or at an advanced stage of development:

• Oncology: nanoparticles and liposomes deliver chemotherapy drugs directly to tumor tissue, reducing systemic toxicity.
• Diagnostic imaging: quantum dots, fluorescent semiconductor nanocrystals, can be used as contrast agents to visualize cells and tissues at the molecular level.
• Antimicrobial medical devices: silver nanoparticles are incorporated into catheters and other devices because of their ability to limit bacterial biofilm formation.
• Topical delivery: nanostructured formulations can improve the penetration of active ingredients through the skin or mucous membranes, a principle that can be applied in both pharmaceutical and cosmetic products.

The common principle behind all these applications is the same: a well-designed nanoparticle protects the active ingredient, directs it toward the appropriate target, and controls its release over time.

From Research to Production: Formulation and Scale-Up Challenges

Designing a nanoparticle that works in the laboratory is only half the challenge. For companies developing nanotechnology-based pharmaceuticals or cosmetics, the more complex task is making that formulation reproducible at industrial scale while maintaining consistent stability, safety, and dosage from one batch to another.

This is precisely the type of work Nanomnia focuses on. Starting from the active ingredient selected by the client company, the team evaluates the objectives to be achieved, such as increased bioavailability, resistance to UV radiation or temperature, and long-term stability. It then develops an encapsulated formulation that is first tested in vitro and, where required, under real-world conditions.

Working with a partner specialized in encapsulation also provides access to dedicated equipment such as spray dryers, microfluidizers, and emulsification systems, together with a validation process that has already been applied to a wide variety of active ingredients.

Biocompatibility and Sustainability: The Next Frontier of Medical Nanotechnology

One issue that is becoming increasingly important in the sector is the biocompatibility of the materials used to build nanoparticles. Not all medical nanotechnologies are created in the same way. Some formulations rely on persistent synthetic polymers, while others are based entirely on biocompatible and biodegradable materials.

This distinction is particularly important for pharmaceutical and cosmetics companies that need to adapt to European regulations on microplastics, which will restrict the use of these materials in a broad range of products from 2028.

Nanomnia has been working in this area for years, developing encapsulation systems based on biocompatible and biodegradable materials such as polysaccharides, lipids, proteins, and natural resins. These materials can provide the same controlled-release and active ingredient protection performance without leaving microplastic residues in the environment.

Frequently Asked Questions About Medical Nanotechnology